Nuclear factor-kappa B and its role in inflammatory lung disease
Khalid Saad Alharbi,Neeraj Kumar Fuloria,Shivkanya Fuloria,Sk Batin Rahman,Waleed Hassan Al-Malki,Mohammad Arshad Javed Shaikh,Lakshmi Thangavelu,Sachin K Singh,Venkata Sita Rama Raju Allam,Niraj Kumar Jha,Dinesh Kumar Chellappan,Kamal Dua,Gaurav Gupta
DOI: https://doi.org/10.1016/j.cbi.2021.109568
2021-08-25
Abstract:Nuclear factor-kappa B, involved in inflammation, host immune response, cell adhesion, growth signals, cell proliferation, cell differentiation, and apoptosis defense, is a dimeric transcription factor. Inflammation is a key component of many common respiratory disorders, including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, and acute respiratory distress syndrome. Many basic transcription factors are found in NF-κB signaling, which is a member of the Rel protein family. Five members of this family c-REL, NF-κB2 (p100/p52), RelA (p65), NF-κB1 (p105/p50), RelB, and RelA (p65) produce 5 transcriptionally active molecules. Proinflammatory cytokines, T lymphocyte, and B lymphocyte cell mitogens, lipopolysaccharides, bacteria, viral proteins, viruses, double-stranded RNA, oxidative stress, physical exertion, various chemotherapeutics are the stimulus responsible for NF-κB activation. NF-κB act as a principal component for several common respiratory illnesses, such as asthma, lung cancer, pulmonary fibrosis, COPD as well as infectious diseases like pneumonia, tuberculosis, COVID-19. Inflammatory lung disease, especially COVID-19, can make NF-κB a key target for drug production.